-
SoftBank intends to work with Nomura Holdings to promote the IPO of the company's Japanese telecommunications business
Time of Update: 2022-12-26
The report quoted people familiar with the matter as saying that SoftBank plans to sell most of the shares issued by the IPO to a group of individuals in Japan.
-
Fangda Group raised 460 million yuan to invest in photovoltaic projects
Time of Update: 2022-11-22
It is reported that with the approval of the China Securities Regulatory Commission (CSRC), Fangda Group Co.
It is reported that with the approval of the China Securities Regulatory Commission (CSRC), Fangda Group Co.
-
300 billion pharmaceutical giants terminated equity incentives, and a new response is coming
Time of Update: 2021-12-30
On the evening of December 8, Hengrui Medicine issued an announcement stating that the company’s board of directors has decided to terminate the implementation of the 2020 restricted stock incentive plan and repurchase and cancel related restricted stocks that have been granted but not yet lifted .
-
Saisheng Pharmaceutical is listed on the main board of the Hong Kong Stock Exchange
Time of Update: 2021-03-23
In the previous public offering, the initial offer shares offered by Saisheng Pharmaceutical have been moderately over-subscribed, which is equivalent to approximately 1,068.
05 times the 11,599,000 Hong Kong offer shares initially available for subscription under the Hong Kong Public Offering.
-
Anti-tumor monoantino sing-off drug and small molecule-targeted drug is a hot spot in the development of domestic pharmaceutical enterprises
Time of Update: 2020-07-17
Guide: Unlike the U.S market, Chinese companies, with the exception of Kingsley (Legendary Bio), do not have listed companies reporting cell therapy data, but the PD-1 monoab as the representative of
